아시아 태평양 혈장 및 혈장 유래 의약품 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2032년까지의 전망

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Healthcare Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 무료 샘플 보고서 무료 샘플 보고서 구매하기 전에 문의 구매하기 전에 문의 지금 구매 지금 구매

아시아 태평양 혈장 및 혈장 유래 의약품 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2032년까지의 전망

  • Healthcare
  • Published Report
  • Jun 2025
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 421
  • 그림 수: 43
  • Author : Sachin Pawar
지금 구매 지금 구매 샘플요청 샘플요청
Nucleus Nucleus

민첩한 공급망 컨설팅으로 관세 문제를 극복하세요

공급망 생태계 분석이 이제 DBMR 보고서의 일부가 되었습니다

Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Chart Image USD 11.61 Billion USD 5.96 Billion 2024 2032
Diagram 예측 기간
 2025 –2032
Diagram 시장 규모(기준 연도)
 USD 11.61 Billion
Diagram 시장 규모(예측 연도)
 USD 5.96 Billion
Diagram 연평균 성장률
 %
Diagram 주요 시장 플레이어
  • CSL
  • Takeda Pharmaceutical Company Limited
  • Grifols
  • S.A.
  • Octapharma AG

아시아 태평양 혈장 및 혈장 유래 의약품 시장 세분화, 제품별( 면역글로불린 , 응고 인자(출혈 장애용), 알부민 (혈장 용적 확장제), 프로테아제 억제제(유전적 결핍용), 단일클론 항체(혈장 세포에서 유래) 및 기타 혈장 유래 단백질), 응용 분야(면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학 , 류마티스학 및 기타 응용 분야), 처리 기술(이온 교환 크로마토그래피, 친화성 크로마토그래피, 극저온 침전, 초미세 여과 및 미세 여과), 모드(현대 및 전통 혈장 분획), 최종 사용자(병원 및 진료소, 연구실, 학술 기관 및 기타), 유통 채널(직접 입찰, 제3자 유통업체 및 기타) - 산업 동향 및 2032년까지의 예측

혈장 및 혈장 유래 의약품 시장

혈장 및 혈장 유래 의약품 시장 규모

  • 아시아 태평양 혈장 및 혈장 유래 의약품 시장은 2024년에 59억 6천만 달러 규모로 평가되었으며, 예측 기간 동안 8.73%의 CAGR 로 2032년까지 116억 1천만 달러 에 도달할 것으로 예상됩니다 .
  • 시장 성장은 주로 희귀 및 만성 질환의 유병률 증가에 의해 촉진됩니다.
  • 더욱이, 혈장 및 혈장 유래 의약품의 혈장 분획 기술 발전이 두드러지고 있습니다. 이러한 융합 요인들은 혈장 및 혈장 유래 의약품 솔루션의 도입을 가속화하여 업계 성장을 크게 촉진하고 있습니다.

혈장 및 혈장 유래 의약품 시장 분석

  • 혈우병, 면역결핍 장애, 자가면역 질환과 같은 질환을 치료하는 데 있어 혈장 유래 치료법에 대한 수요 증가로 시장이 확대되고 있으며, 이는 수혈 의학에 대한 인식이 높아지고 발전함에 따라 뒷받침되고 있습니다.
  • 혈액 수집, 분획 및 냉장 물류 분야의 기술 발전으로 제품 품질과 유통 기한이 향상되어 아시아 태평양 지역의 병원, 외상 센터 및 진단 실험실에서 더 폭넓은 도입이 촉진되고 있습니다.
  • 중국은 개선된 의료 인프라, 혈장 치료제 수요 증가, 정부 지원 확대, 만성 및 감염성 질환 유병률 증가로 인해 2025년 혈장 및 혈장 유래 의약품 시장 점유율 24.89%를 기록하며 시장을 장악할 것으로 예상됩니다.
  • 중국은 의료 투자 증가, 만성 및 감염성 질환 유병률 증가, 진단 시설 개선, 혈액 안전에 대한 인식 제고, 혈장 치료 접근성 및 인프라 강화를 위한 정부 이니셔티브로 인해 시장에서 가장 빠르게 성장하는 지역이 될 것으로 예상됩니다.
  • 면역글로불린 부문은 표적 치료에 대한 수요 증가, 정제 기술 개선, 면역 관련 질환 유병률 증가로 인해 2025년에 41.42%의 점유율로 시장을 지배할 것으로 예상됩니다.

보고서 범위 및 혈장 및 혈장 유래 의약품 시장 세분화

속성

혈장 및 혈장 유래 의약품 주요 시장 통찰력

다루는 세그먼트
  • 부산물: 면역글로불린, 응고인자(출혈 질환용), 알부민(혈장량 확장제), 프로테아제 억제제(유전적 결핍용), 단일클론 항체(혈장 세포에서 유래), 기타 혈장 유래 단백질
  • 응용 분야별: 면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학, 류마티스학 및 기타 응용 분야
  • 처리 기술 이온 교환 크로마토그래피, 친화성 크로마토그래피, 극저온 침전, 초미세 여과 및 미세 여과
  • 모드별 현대식 및 전통식 플라즈마 분획
  • 최종 사용자별: 병원 및 진료소, 연구실, 학술 기관 및 기타
  • 유통 채널별: 직접 입찰, 제3자 유통업체 및 기타

포함 국가
  • 중국
  • 일본
  • 대한민국
  • 호주
  • 인도
  • 말레이시아
  • 태국
  • 싱가포르
  • 필리핀 제도
  • 인도네시아 공화국
  • 뉴질랜드
  • 베트남
  • 대만
  • 아시아 태평양의 나머지 지역

주요 시장 참여자
  • CSL(호주)
  • 다케다제약 주식회사(일본)
  • 그리폴스, SA(스페인)
  • 옥타파마 AG(스위스)
  • 케드리온(이탈리아)
  • 에그로스(호주)
  • Bharat Serums(인도)
  • Biotest AG(독일)
  • 프레제니우스 카비 AG(독일)
  • GC바이오파마 법인(한국)
  • ICHOR(인도)
  • Intas Pharmaceuticals Ltd.(인도)
  • 카마다제약(이스라엘)
  • KM Biologics(일본)
  • PlasmaGen BioSciences Pvt. Ltd. (인도)
  • 프로라이언트 헬스 앤 바이올로지컬스(미국)
  • 프로메아(인도)
  • Reliance Life Sciences(인도)
  • 쓰촨 원달 솽 제약 유한회사(중국)
  • SK플라즈마(한국)
  • Synthaverse SA(폴란드)
  • 타이방 바이오 그룹 유한회사(중국)
  • VIRCHOW BIOTECH(인도)

시장 기회
  • 수율 향상 및 비용 절감을 위한 플라즈마 처리 기술의 발전
  • 보상 프레임워크와 희귀 질환 치료에 대한 정부의 집중 강화

부가가치 데이터 정보 세트

Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함됩니다.

혈장 및 혈장 유래 의약품 시장 동향

“희귀 및 만성 질환 유병률 증가”

  • 혈장 및 혈장 유래 의약품 시장의 주요 원동력은 진단 기술의 발전과 의료 서비스 제공자 및 환자의 인식 제고로 인해 아시아 태평양 지역에서 희귀 및 만성 질환의 유병률이 증가하고 있다는 것입니다.
  • 예를 들어, 2025년 4월 미국 질병통제예방센터(CDC) 데이터에 따르면 미국 성인의 76.4%가 최소 한 가지 만성 질환을 앓고 있었고, 51.4%는 여러 질환을 앓고 있었습니다. 젊은 성인에서도 관찰되는 이러한 증가 추세는 특히 혈우병, 원발성 면역결핍증, 폰 빌레브란트병과 같은 질환에 대한 평생 치료에 대한 수요를 증가시켰습니다.
  • 면역글로불린, 응고인자, 알부민과 같은 혈장 유래 치료제는 이러한 평생 질환을 관리하는 데 필수적입니다. 원발성 면역결핍증 환자는 면역 지원을 위해 IVIG에 의존하는 반면, 혈우병 환자는 출혈을 예방하기 위해 정기적인 응고인자 주입이 필요합니다.
  • 전 세계 인구 고령화로 인해 이러한 추세가 더욱 가속화되고 있으며, 노인들은 간경변, 다발성 골수종, 염증성 질환과 같은 질환에 점점 더 많이 시달리고 있으며 이러한 질환들은 모두 혈장 유래 개입을 필요로 합니다.
  • 2025년 3월, PMC에 발표된 연구는 희귀 질환, 특히 소아 환자의 전 세계적인 엄청난 부담을 강조했습니다. 유전체 의학과 희귀의약품 개발의 진전에도 불구하고, 진단 지연과 제한된 치료 옵션은 여전히 ​​남아 있으며, 이는 다학제적이고 지속적인 치료의 필요성을 강조합니다.
  • 안전하고 효과적이며 고품질의 혈장 유래 치료법에 대한 수요 증가는 혈장 및 혈장 유래 의약품 시장을 견인하는 핵심 요인입니다. 이러한 제품은 아시아 태평양 지역의 평생 질병을 관리하고 충족되지 않은 의료적 요구를 해결하는 데 중요한 역할을 하기 때문입니다.

혈장 및 혈장 유래 의약품 시장 동향

운전사

“노인 인구 확대”

  • 혈장 및 혈장 유래 의료 제품에 대한 수요 증가는 면역 체계 장애, 신경 질환, 간 합병증 및 면역글로불린, 알부민, 응고 인자를 포함한 혈장 기반 치료법이 필요한 혈액 관련 문제와 같은 만성 및 퇴행성 질환에 더 취약한 고령화된 세계 인구에 의해 크게 촉진됩니다.
  • 예를 들어, 2025년 3월, PMC에 게재된 연구에서는 2010년부터 2024년까지 미국 국립 입원 환자 표본(NIS) 데이터를 분석하여 고령 인구의 급격한 증가로 인해 입원, 입원 기간 연장, 그리고 재입원율이 크게 증가한 것으로 나타났습니다. 만성 질환과 복합 질환으로 인한 이러한 추세는 의료 시스템의 부담 증가와 그에 따른 혈장 유래 치료제 수요 증가를 보여줍니다.
  • 나이가 들면서 면역 체계가 약화되어 감염 및 자가면역 질환에 대한 취약성이 증가합니다. 면역글로불린 요법은 만성 염증성 탈수초성 다발신경병증(CIDP)과 같은 질환 치료에 자주 사용되는 반면, 알부민은 고령 환자의 수술 및 중환자 치료 시 체액 균형 조절에 필수적입니다.
  • 일본, 독일, 이탈리아, 미국처럼 고령 인구 비율이 높은 국가에서는 PDMP(혈장분리막) 소비가 지속적으로 증가하고 있습니다. 이러한 인구학적 추세는 국가 의료 시스템에 중단 없는 공급망과 충분한 혈장 수집을 보장해야 하는 엄청난 부담을 안겨줍니다.
  • 세계보건기구(WHO) 추산에 따르면 2023년 11억 명이었던 전 세계 60세 이상 인구가 2050년에는 21억 명으로 증가할 것으로 예상됨에 따라 노인 의료의 중요성이 더욱 강조되고 있습니다. 이러한 인구학적 변화는 장기적인 치료 지원의 필요성을 증폭시킬 뿐만 아니라, 아시아 태평양 지역에서 노인 인구를 PDMP(노인 의료 서비스)의 핵심적이고 지속적인 시장 부문으로 자리매김하게 합니다.

제지/도전

“ 고비용 및 복잡한 제조 공정 ”

  • 혈장 및 혈장 유래 의약품 제조에 따르는 높은 비용과 복잡성은 시장 확장에 큰 걸림돌이 됩니다. 이 공정은 엄격한 혈장 채취 프로토콜, 광범위한 병원균 검사, 그리고 무균 및 GMP 준수 환경에서의 다단계 분획을 요구하기 때문에 생산에 막대한 자원과 시간이 소요될 수 있습니다.
  • 예를 들어, Aykon Biosciences의 상세 분석에 따르면 혈장 유래 치료제와 같은 복잡한 생물학적 제제 제조는 값비싼 원자재, 숙련된 인력 요구, 그리고 점점 더 엄격해지는 규제 준수 요구로 인해 비용 압박이 증가하고 있습니다. 전문화되고 개인화된 치료법으로의 전환은 비용을 더욱 증가시켜 첨단 기술과 엄격한 품질 보증 시스템을 필요로 합니다.
  • 또한, PDMP의 제조 주기는 최대 12개월까지 길어질 수 있으며, 공정 전반에 걸쳐 보관 및 운송을 위한 콜드체인 물류가 필요합니다. 이러한 요인들은 자본 및 운영 비용을 크게 증가시켜 확장성을 제한하고 소규모 업체와 개발도상국의 시장 참여를 저해합니다.
  • 생산 비용 집약적인 특성 또한 최종 제품 가격 상승에 영향을 미쳐, 특히 의료 예산이 부족한 저소득 및 중소득 국가에서 접근성과 구매력을 저하시킵니다. 이러한 재정적 부담은 증가하는 글로벌 수요를 충족하는 데 어려움을 야기하여, 전 세계적으로 PDMP의 광범위한 도입을 저해합니다.
  • 지속적인 기술 혁신을 통해 비용 효율성이 점진적으로 향상될 수 있지만, 현재의 높은 생산 및 가공 비용은 여전히 ​​주요 제약 요소로 남아 있습니다. 제조 기술 개선, 공여 인프라 확대, 그리고 적극적인 공중 보건 기금 지원을 통해 이러한 과제를 해결하는 것은 더 넓은 시장 접근성과 공평한 치료 보장을 확보하는 데 필수적입니다.

혈장 및 혈장 유래 의약품 시장 범위

시장은 제품, 응용 분야, 처리 기술, 모드, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다.

  • 제품별

제품별로 시장은 면역글로불린, 응고인자(출혈 질환 치료), 알부민(혈장량 증가제), 프로테아제 억제제(유전적 결핍 치료), 단일클론 항체(혈장 세포 유래) 및 기타 혈장 유래 단백질로 세분화됩니다. 2025년에는 면역글로불린 부문이 면역결핍 진단 증가, 자가면역 질환, 그리고 정맥 면역글로불린(IVIG) 사용 증가에 힘입어 41.42%의 시장 점유율을 기록하며 시장을 주도할 것으로 예상됩니다.

응고 인자(출혈성 질환 치료) 부문은 혈우병 환자 증가, 진단 접근성 향상, 정부 지원, 재조합 및 혈장 유래 치료법 사용 확대에 힘입어 2025년부터 2032년까지 8.94%의 가장 빠른 성장률을 보일 것으로 예상됩니다.

  • 응용 프로그램별

응용 분야별로 시장은 면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학, 류마티스학 및 기타 분야로 세분화됩니다. 면역학 분야는 2025년 시장 매출 점유율이 가장 높았는데, 이는 원발성 면역결핍증 및 자가면역 질환 치료에 널리 사용되고 있으며, 정맥주사 면역글로불린(IVIG)에 대한 전 세계 수요 증가에 힘입은 것입니다.

면역학 분야는 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 자가면역 질환의 유병률 증가, 인구 고령화, 면역글로불린 치료법의 임상 적용 확대에 힘입은 것입니다.

  • 가공 기술로

처리 기술을 기준으로 시장은 이온 교환 크로마토그래피, 친화성 크로마토그래피, 동결침전, 한외여과, 정밀여과로 구분됩니다. 이온 교환 크로마토그래피 부문은 면역글로불린, 알부민, 응고 인자와 같은 혈장 단백질 정제에 있어 높은 효율, 확장성, 그리고 효과성을 바탕으로 2025년 시장 매출 점유율 1위를 차지했습니다.

친화성 크로마토그래피 부문은 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 높은 특이성, 표적 단백질 분리 능력, 고급 생물학적 정제 분야에서의 채택 증가로 선호됩니다.

  • 모드별

시장은 방식에 따라 현대식 혈장 분획법과 전통식 혈장 분획법으로 구분됩니다. 현대식 혈장 분획법은 첨단 처리 기술, 더 높은 제품 순도, 향상된 안전성 프로파일, 그리고 재조합 및 고수율 혈장 유래 치료법의 도입 증가를 주도하며 2025년 시장 매출 점유율 1위를 차지했습니다.

현대 분야는 정제 기술의 혁신, 더 안전한 생물학 제제에 대한 수요 증가, 차세대 플라즈마 처리 기술에 대한 투자 증가로 인해 2025년부터 2032년까지 가장 빠른 CAGR을 보일 것으로 예상됩니다.

  • 최종 사용자별

최종 사용자 기준으로 시장은 병원 및 진료소, 연구소, 학술 기관 등으로 세분화됩니다. 병원 및 진료소 부문은 2025년에 가장 큰 시장 매출 점유율을 차지했는데, 이는 높은 환자 수, 전문 치료 접근성, 만성 질환 치료 증가, 그리고 첨단 혈장 유래 치료법 접근성 덕분입니다.

병원 및 진료소 부문도 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 의료 인프라 확장, 입원 환자 증가, 복잡한 질환에 대한 플라스마 치료법 의존도 증가에 힘입은 것입니다.

  • 유통 채널별

유통 채널을 기준으로 시장은 직접 입찰, 제3자 유통업체, 그리고 기타 업체로 구분됩니다. 직접 입찰 부문은 정부 기관의 대량 구매, 비용 효율성, 안정적인 공급망, 그리고 혈장 유래 의약품에 대한 공공 부문 투자 증가에 힘입어 2025년 시장 매출 점유율이 가장 높았습니다.

직접 입찰 부문은 정부 의료 프로그램 확대, 중앙 조달 정책 강화, 비용 효율적인 대규모 혈장 치료 유통에 대한 수요 증가에 힘입어 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상됩니다.

혈장 및 혈장 유래 의약품 시장 지역 분석

  • 중국은 24.89%의 가장 큰 매출 점유율로 혈장 및 혈장 유래 의료 제품 시장을 장악하고 있으며, 첨단 의료 인프라, 희귀 및 만성 질환의 진단율 증가, 1인당 의료비 지출 증가로 인해 2025년에는 9.95%의 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
  • 국가의 강력한 규제 프레임워크, 견고한 상환 시스템, Grifols, CSL Behring, Takeda와 같은 주요 시장 참여자의 존재는 혈장 수집 및 치료 유통 분야에서 아시아 태평양 지역의 리더십에 기여합니다.
  • 중국, 일본, 인도 등 주요 경제권에서는 생물약학 R&D에 막대한 투자를 하고 있으며, 혈장 수집 네트워크를 확대하고 면역학, 혈액학, 신경학 분야에서 혈장 유래 치료법에 대한 접근성을 개선하고 있습니다.

일본 혈장 및 혈장 유래 의약품 시장 분석

일본은 2025년부터 2032년까지 아시아 태평양 지역에서 강력한 성장을 보일 것으로 예상됩니다. 이는 탄탄한 의료 생태계, 희귀 및 만성 질환 환자 증가, 그리고 혈장 기증을 장려하는 정부의 적극적인 정책에 기인합니다. 일본은 혈장 수집 센터가 많고 PDMP(혈장분획제제) 승인이 가속화되어 치료 접근성이 향상되고 시장 확대가 촉진됩니다.

한국 혈장 및 혈장 유래 의약품 시장 분석

한국은 보편적 의료 시스템, 희귀 질환에 대한 인식 제고, 그리고 정부의 국내 혈장 수집 역량 강화 투자에 힘입어 2025년부터 2032년까지 이 지역에서 상당한 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 전략적 파트너십과 생물의약품 제조 분야의 발전은 캐나다의 PDMP(혈장 생산 및 생산) 분야에서의 입지를 강화하고 있습니다.

혈장 및 혈장 유래 의약품 시장 점유율

혈장 및 혈장 유래 의약품 산업은 주로 다음을 포함한 잘 확립된 회사들이 주도하고 있습니다.

  • CSL(호주)
  • 다케다제약 주식회사(일본)
  • 그리폴스, SA(스페인)
  • 옥타파마 AG(스위스)
  • 케드리온(이탈리아)
  • 에그로스(호주)
  • Bharat Serums(인도)
  • Biotest AG(독일)
  • 프레제니우스 카비 AG(독일)
  • GC바이오파마 법인(한국)
  • ICHOR(인도)
  • Intas Pharmaceuticals Ltd.(인도)
  • 카마다제약(이스라엘)
  • KM Biologics(일본)
  • PlasmaGen BioSciences Pvt. Ltd. (인도)
  • 프로라이언트 헬스 앤 바이올로지컬스(미국)
  • 프로메아(인도)
  • Reliance Life Sciences(인도)
  • 쓰촨 원달 솽 제약 유한회사(중국)
  • SK플라즈마(한국)
  • Synthaverse SA(폴란드)
  • 타이방 바이오 그룹 유한회사(중국)
  • VIRCHOW BIOTECH(인도)

혈장 및 혈장 유래 의약품 시장의 최신 동향

  • 2024년 11월, CSL Plasma는 콜로라도주 덴버 인근 6개 미국 헌혈 센터에 첨단 Rika 혈장 헌혈 시스템 도입을 확대했습니다. Terumo Blood & Cell Technologies와 공동 개발한 이 새로운 기기는 헌혈자의 편의성, 안전성, 효율성을 향상하는 동시에 채혈 시간을 약 30% 단축했습니다.
  • 2022년 12월, CSL은 호주 빅토리아주에 브로드메도우즈 혈장 분획 시설을 준공했습니다. 이 시설은 남반구 최대 규모의 혈장 곡물 처리 시설입니다. 연간 920만 리터의 혈장 환산량을 처리할 수 있는 9억 달러 규모의 이 시설은 면역 결핍, 신경 질환, 그리고 이식이나 화상과 같은 중증 질환을 치료하는 혈장 기반 치료법에 대한 전 세계 수요를 충족합니다.
  • 2024년 6월, 다케다는 용량 기준 세계 최고 수준인 로스앤젤레스 혈장 분획 시설의 3천만 달러 확장을 발표했습니다. 이번 시설 확충을 통해 연간 최대 200만 리터의 생산량이 증가할 것으로 예상되며, 면역결핍 및 출혈성 질환 치료에 사용되는 혈장 유래 치료제에 대한 전 세계 수요 증가에 대응할 수 있을 것으로 기대됩니다.
  • 2023년, 다케다는 일본 오사카에 약 7억 6,500만 달러를 투자하여 새로운 혈장 유래 치료제 생산 공장을 건설했습니다. 이는 기존 나리타 공장의 생산 능력을 거의 5배로 늘리는 것입니다. 이 시설은 2030년까지 완전 가동될 예정이며, 일본과 글로벌 시장 모두에 서비스를 제공할 것입니다.
  • 2025년 3월 Grifols는 Inpeco와 협력하여 고급 자동화 로봇(FlexLab X), 진단 및 시약을 통합하여 수혈에서 처리량이 높고 안전하고 추적 가능한 혈액 및 혈장 검사를 위한 "미래의 실험실"을 만들었습니다. 의학 실험실은 생물학적 샘플을 분석하여 질병을 진단, 모니터링 및 연구합니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.1.1 POLITICAL FACTORS

4.1.2 ECONOMIC FACTORS

4.1.3 SOCIAL FACTORS

4.1.4 TECHNOLOGICAL FACTORS

4.1.5 ENVIRONMENTAL FACTORS

4.1.6 LEGAL FACTORS

4.2 PORTER’S FIVE FORCES

4.2.1 THREAT OF NEW ENTRANTS

4.2.2 BARGAINING POWER OF SUPPLIERS

4.2.3 BARGAINING POWER OF BUYERS

4.2.4 THREAT OF SUBSTITUTES

4.2.5 INDUSTRY RIVALRY

4.3 SUPPLY CHAIN IMPACT ON THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

4.3.1 OVERVIEW

4.3.2 RAW MATERIAL AVAILABILITY

4.3.3 MANUFACTURING CAPACITY

4.3.4 LOGISTICS AND LAST-MILE HURDLES

4.3.5 PRICING MODELS AND MARKET POSITIONING

4.4 INNOVATION STRATEGIES

4.4.1 KEY INNOVATION STRATEGIES

4.4.2 EMERGING DELIVERY TECHNIQUES

4.4.3 STRATEGIC IMPLICATIONS

4.4.4 CONCLUSION

4.5 RISK AND MITIGATION

4.6 VENDOR SELECTION DYNAMICS

4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE

4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY

4.6.3 CLINICAL EFFICACY AND INNOVATION

4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY

4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE

4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY

4.6.7 CONCLUSION

4.7 TARIFFS AND THEIR IMPACT ON MARKET

4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS

4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE

4.7.3 VENDOR SELECTION CRITERIA DYNAMICS

4.7.4 IMPACT ON SUPPLY CHAIN

4.7.5 IMPACT ON PRICES

4.7.6 REGULATORY INCLINATION

4.7.6.1 GCC TRADE ALIGNMENT & FTAS

4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS

4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE

4.7.6.4 DOMESTIC COURSE OF CORRECTION

5 REGULATION COVERAGE

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES

6.1.2 EXPANDING GERIATRIC POPULATION

6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION

6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT

6.2 RESTRAINTS

6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS

6.2.2 LACK OF PLASMA SUPPLY AND DONOR

6.3 OPPORTUNITIES

6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS

6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT

6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN ASIA-PACIFIC MARKET PENETRATION

6.4 CHALLENGES

6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES

6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION

7 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT

7.1 OVERVIEW

7.2 IMMUNOGLOBULINS

7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS)

7.4 ALBUMIN (PLASMA VOLUME EXPANDER)

7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)

7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS)

7.7 OTHER PLASMA DERIVED PROTEINS

8 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 IMMUNOLOGY

8.3 HEMATOLOGY

8.4 CRITICAL CARE

8.5 NEUROLOGY

8.6 PULMONOLOGY

8.7 HAEMATO-ONCOLOGY

8.8 RHEUMATOLOGY

8.9 OTHER APPLICATIONS

9 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 ION EXCHANGE CHROMATOGRAPHY

9.3 AFFINITY CHROMATOGRAPHY

9.4 CRYOPRECIPITATION

9.5 ULTRAFILTRATION

9.6 MICROFILTRATION

10 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE

10.1 OVERVIEW

10.2 MODERN

10.3 TRADITIONAL PLASMA FRACTIONATION

11 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS & CLINICS

11.3 RESEARCH LABS

11.4 ACADEMIC INSTITUTES

11.5 OTHERS

12 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 THIRD PARTY DISTRIBUTORS

12.4 OTHERS

13 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION

13.1 ASIA-PACIFIC

13.1.1 CHINA

13.1.2 JAPAN

13.1.3 SOUTH KOREA

13.1.4 AUSTRALIA

13.1.5 INDIA

13.1.6 MALAYSIA

13.1.7 THAILAND

13.1.8 SINGAPORE

13.1.9 PHILIPPINES

13.1.10 INDONESIA

13.1.11 NEW ZEALAND

13.1.12 VIETNAM

13.1.13 TAIWAN

13.1.14 REST OF ASIA-PACIFIC

14 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 CSL

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 GRIFOLS, S.A.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 OCTAPHARMA AG

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 KEDRION

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 ADMA BIOLOGICS, INC

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 AEGROS

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BHARAT SERUMS

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 BIOTEST AG.

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 FRESENIUS KABI AG

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 GC BIOPHARMA CORPORATE

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 ICHOR

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 INTAS PHARMACEUTICALS LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 KAMADA PHARMACEUTICALS

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 KM BIOLOGICS

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 LFB

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 PLASMAGEN BIOSCIENCES PVT. LTD.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 PROLIANT HEALTH & BIOLOGICALS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 PROMEA

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 RELIANCE LIFE SCIENCES

16.20.1 COMPANY SNAPSHOT

16.20.2 BUSINESS PORTFOLIO

16.20.3 RECENT DEVELOPMENT

16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD.

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 SK PLASMA

16.22.1 COMPANY SNAPSHOT

16.22.2 PRODUCT PORTFOLIO

16.22.3 RECENT DEVELOPMENT

16.23 SYNTHAVERSE S. A.

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PRODUCT PORTFOLIO

16.23.4 RECENT DEVELOPMENTS

16.24 TAIBANG BIO GROUP CO., LTD

16.24.1 COMPANY SNAPSHOT

16.24.2 PRODUCT PORTFOLIO

16.24.3 RECENT DEVELOPMENT

16.25 VIRCHOW BIOTECH

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

표 목록

TABLE 1 REGULATORY FRAMEWORK AND GUIDELINES

TABLE 2 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC COAGULATION FACTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC FACTOR IX IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC FACTOR VIII IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC FIBRINOGEN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC VON WILLEBRAND FACTOR (VWF) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 18 IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC ALBUMIN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS )IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2032 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC IMMUNOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC HEMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC CRITICAL CARE IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC NEUROLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC PULMONOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC HEMATOLOGY -ONCOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC RHEUMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC OTHER APPLICATIONS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY, 2025-2032 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC ION EXCHANGE CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC AFFINITY CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC CRYOPRECIPITATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC ULTRAFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC MICROFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2025-2032 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC MODERN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC TRADITIONAL PLASMA FRACTIONATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2032 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC HOSPITALS & CLINICS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC RESEARCH LABS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC ACADEMIC INSTITUTES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC OTHERS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC DIRECT TENDERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC THIRD PARTY DISTRIBUTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC OTHERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 80 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 83 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 84 CHINA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 CHINA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 CHINA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 CHINA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 CHINA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 CHINA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 CHINA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 CHINA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 CHINA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 CHINA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 94 CHINA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 CHINA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 CHINA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 CHINA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 CHINA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 CHINA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 CHINA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 CHINA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 CHINA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 CHINA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 105 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 106 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 107 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 108 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 109 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 110 JAPAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 JAPAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 JAPAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 JAPAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 JAPAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 JAPAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 JAPAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 JAPAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 JAPAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 JAPAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 JAPAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 JAPAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 JAPAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 JAPAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 JAPAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 JAPAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 JAPAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 JAPAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 JAPAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 JAPAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 131 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 132 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 133 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 134 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 135 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 136 SOUTH KOREA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 SOUTH KOREA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 SOUTH KOREA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 SOUTH KOREA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 SOUTH KOREA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 SOUTH KOREA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 SOUTH KOREA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 SOUTH KOREA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 SOUTH KOREA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 SOUTH KOREA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 SOUTH KOREA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 SOUTH KOREA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 SOUTH KOREA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 SOUTH KOREA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SOUTH KOREA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 SOUTH KOREA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 SOUTH KOREA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 SOUTH KOREA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SOUTH KOREA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SOUTH KOREA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 157 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 158 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 159 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 160 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 161 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 162 AUSTRALIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 AUSTRALIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 AUSTRALIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 AUSTRALIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 AUSTRALIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 AUSTRALIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 AUSTRALIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 AUSTRALIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 AUSTRALIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 AUSTRALIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 AUSTRALIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 AUSTRALIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 174 AUSTRALIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 AUSTRALIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 AUSTRALIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 AUSTRALIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 AUSTRALIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 AUSTRALIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 AUSTRALIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 AUSTRALIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 183 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 184 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 185 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 186 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 187 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 188 INDIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 INDIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 INDIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 INDIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 INDIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 INDIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 INDIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 INDIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 INDIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 INDIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 INDIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 INDIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 INDIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 INDIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 INDIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 INDIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 INDIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 INDIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 INDIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 INDIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 209 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 210 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 211 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 212 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 213 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 214 MALAYSIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 MALAYSIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 MALAYSIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 MALAYSIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 MALAYSIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 MALAYSIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 MALAYSIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 MALAYSIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 MALAYSIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 MALAYSIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 MALAYSIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 MALAYSIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 MALAYSIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 MALAYSIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 MALAYSIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 MALAYSIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 MALAYSIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 MALAYSIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 MALAYSIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 MALAYSIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 235 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 236 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 237 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 238 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 239 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 240 THAILAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 THAILAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 THAILAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 THAILAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 THAILAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 THAILAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 THAILAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 THAILAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 THAILAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 THAILAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 THAILAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 THAILAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 THAILAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 THAILAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 THAILAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 THAILAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 THAILAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 THAILAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 THAILAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 THAILAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 261 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 262 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 263 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 264 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 265 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 266 SINGAPORE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 SINGAPORE INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 SINGAPORE INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 SINGAPORE COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 SINGAPORE FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 SINGAPORE RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 SINGAPORE FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 SINGAPORE RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 SINGAPORE FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 SINGAPORE PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 SINGAPORE VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 SINGAPORE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 SINGAPORE FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 SINGAPORE ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 SINGAPORE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 SINGAPORE ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 SINGAPORE C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 SINGAPORE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 SINGAPORE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 SINGAPORE ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 287 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 288 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 289 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 290 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 291 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 292 PHILIPPINES IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 PHILIPPINES INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 PHILIPPINES INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 PHILIPPINES COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 PHILIPPINES FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 PHILIPPINES RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 PHILIPPINES FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 PHILIPPINES RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 PHILIPPINES FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 PHILIPPINES PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 PHILIPPINES VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 303 PHILIPPINES FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 PHILIPPINES FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 PHILIPPINES ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 PHILIPPINES PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 PHILIPPINES ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 PHILIPPINES C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 PHILIPPINES MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 PHILIPPINES OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 PHILIPPINES ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 313 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 314 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 315 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 316 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 317 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 318 INDONESIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 INDONESIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 INDONESIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 INDONESIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 INDONESIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 INDONESIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 INDONESIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 INDONESIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 INDONESIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 INDONESIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 INDONESIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 INDONESIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 INDONESIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 INDONESIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 INDONESIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 INDONESIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 INDONESIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 INDONESIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 INDONESIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 INDONESIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 339 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 340 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 341 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 342 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 343 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 344 NEW ZEALAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 NEW ZEALAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 NEW ZEALAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 NEW ZEALAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 NEW ZEALAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 NEW ZEALAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 NEW ZEALAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 NEW ZEALAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 NEW ZEALAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 NEW ZEALAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 NEW ZEALAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 NEW ZEALAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 NEW ZEALAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 NEW ZEALAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 NEW ZEALAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 NEW ZEALAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 NEW ZEALAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 NEW ZEALAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 NEW ZEALAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 NEW ZEALAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 365 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 366 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 367 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 368 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 369 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 370 VIETNAM IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 VIETNAM INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 VIETNAM INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 VIETNAM COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 VIETNAM FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 VIETNAM RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 VIETNAM FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 VIETNAM RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 378 VIETNAM FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 VIETNAM PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 380 VIETNAM VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 VIETNAM FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 VIETNAM FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 VIETNAM ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 VIETNAM PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 VIETNAM ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 VIETNAM C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 VIETNAM MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 VIETNAM OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 VIETNAM ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 391 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 392 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 393 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 394 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 395 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 396 TAIWAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 TAIWAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 TAIWAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 TAIWAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 TAIWAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 TAIWAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 TAIWAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 TAIWAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 TAIWAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 TAIWAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 TAIWAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 TAIWAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 TAIWAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 TAIWAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 TAIWAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 TAIWAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 TAIWAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 TAIWAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 TAIWAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 TAIWAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 417 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 418 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 419 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 420 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 421 REST OF ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

그림 목록

FIGURE 1 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION

FIGURE 12 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT (2024)

FIGURE 13 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 RISING PREVALENCE OF RARE AND CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 16 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 & 2032

FIGURE 17 PORTER’S FIVE FORCES

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

FIGURE 19 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2024

FIGURE 20 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2025-2032 (USD THOUSAND)

FIGURE 21 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, CAGR (2025-2032) (2025-2032)

FIGURE 22 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2024

FIGURE 24 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)

FIGURE 25 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, CAGR (2025-2032) (2025-2032)

FIGURE 26 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2024

FIGURE 28 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)

FIGURE 29 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, CAGR (2025-2032) (2025-2032)

FIGURE 30 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2024

FIGURE 32 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2025-2032 (USD THOUSAND)

FIGURE 33 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, CAGR (2025-2032) (2025-2032)

FIGURE 34 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2024

FIGURE 36 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 37 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, CAGR (2025-2032) (2025-2032)

FIGURE 38 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 40 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 41 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032) (2025-2032)

FIGURE 42 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY SHARE 2024 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

시장은 아시아 태평양 혈장 및 혈장 유래 의약품 시장 세분화, 제품별( 면역글로불린 , 응고 인자(출혈 장애용), 알부민 (혈장 용적 확장제), 프로테아제 억제제(유전적 결핍용), 단일클론 항체(혈장 세포에서 유래) 및 기타 혈장 유래 단백질), 응용 분야(면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학 , 류마티스학 및 기타 응용 분야), 처리 기술(이온 교환 크로마토그래피, 친화성 크로마토그래피, 극저온 침전, 초미세 여과 및 미세 여과), 모드(현대 및 전통 혈장 분획), 최종 사용자(병원 및 진료소, 연구실, 학술 기관 및 기타), 유통 채널(직접 입찰, 제3자 유통업체 및 기타) - 산업 동향 및 2032년까지의 예측 기준으로 세분화됩니다.
아시아 태평양 혈장 및 혈장 유래 의약품 시장의 시장 규모는 2024년에 11.61 USD Billion USD로 평가되었습니다.
아시아 태평양 혈장 및 혈장 유래 의약품 시장는 2025년부터 2032년까지 연평균 성장률(CAGR) 8.73%로 성장할 것으로 예상됩니다.
시장 내 주요 기업으로는 CSL, Takeda Pharmaceutical Company Limited, Grifols, S.A., Octapharma AG, Kedrion가 포함됩니다.

관련 페이지 탐색

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future